Empirical Wealth Management
PRLD icon

Empirical Wealth Management’s Prelude Therapeutics PRLD Stock Holding History

Empirical Wealth Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$50.2K Buy
+12,841
New +$63K ﹤0.01% 1143

Other funds holding PRLD

Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Empirical Wealth Management's PRLD Position: Q3 2026 in Review

Empirical Wealth Management opened a new position in Prelude Therapeutics (PRLD) in Q3 2026: 12,841 shares worth $50.2K. The stake represents ﹤0.01% of the portfolio and ranks #1143 among its holdings.

7 funds tracked by Wall St. Rank hold PRLD as of Q3 2026.

  • Empirical Wealth Management held 12,841 shares of Prelude Therapeutics worth $50.2K as of Q3 2026.
  • Prelude Therapeutics was a new Empirical Wealth Management position in Q3 2026.
  • Prelude Therapeutics made up ﹤0.01% of Empirical Wealth Management's portfolio in Q3 2026, its #1143 holding.
  • 7 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2026.

Based on Empirical Wealth Management's 13F filing for Q3 2026, filed 27 Oct 2026.